$IBRX

$IBRX - ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle…

$IBRX - ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BC…

$IBRX ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG…

$IBRX - FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease…

$IBRX FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease…

$IBRX Piper Sandler raised the firm's price target on ImmunityBio to $16 from $12 and keeps an Overweight rating on the shares…

$IBRX volatility off FDA headlines…

$IBRX FDA WINS FIRST-EVER APPROVAL FOR ANKTIVA IN BCG-UNRESPONSIVE HIGH-GRADE PAPILLARY-ONLY BLADDER CANCER social media…

$IBRX some vol…

The worst AI slop $IBRX stock pump I've read. And, of course, @DrPatrick approves. -- ADAM F STAT NEWS…

$IBRX - ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium…

$IBRX SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #IBRX ImmunityBio, Inc. : $7.32 Sector: Healthcare | YTD: 🔼+ 258…